The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells

Area of Science:

• Oncology
• Metabolism
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options.
• Metformin, a diabetes drug, shows potential in inhibiting PDAC growth but clinical trials have yielded mixed results.
• Understanding metformin resistance mechanisms is crucial for improving pancreatic cancer treatment.

Purpose of the Study:

• To investigate the molecular mechanisms underlying metformin resistance in pancreatic cancer cells.
• To explore the role of NAD+/NADH homeostasis and NAMPT in mediating metformin's effects.
• To evaluate the efficacy of combining metformin with a NAMPT inhibitor (FK866) in preclinical models.

Main Methods:

• Assessed metformin's impact on mitochondrial complex I and NAD+/NADH ratio in PDAC cell lines.
• Investigated the effect of NAD+ restoring metabolites and NAMPT inhibition on metformin sensitivity.
• Evaluated the combination of metformin and FK866 in vitro and in vivo xenograft models.

Main Results:

• Metformin sensitivity is determined by NAD+/NADH homeostasis; restoring this ratio confers resistance.
• Metformin treatment induces compensatory NAMPT expression, increasing cellular NAD+ levels.
• FK866 sensitized PDAC cells to metformin in vitro and showed differential survival effects in vivo.
• The drug combination reactivated p53 pathway and oxidative stress genes, suggesting cell death mechanisms.

Conclusions:

• NAD+/NADH homeostasis and NAMPT-mediated NAD+ production are key determinants of metformin efficacy in PDAC.
• Targeting NAMPT in combination with metformin may offer a therapeutic strategy for specific pancreatic cancer subtypes.
• Further research into the p53 pathway and oxidative stress is warranted to elucidate synergistic cell death mechanisms.